BiomX Inc. (NYSE American: PHGE) entered into an option agreement on March 31 2026 to acquire control of DFSL, a developer of proprietary laser‑radar (LADAR) detection systems for security, defense, and critical infrastructure applications. The option allows BiomX to exercise control of DFSL upon closing of the underlying transaction, subject to shareholder approval and customary closing conditions. The consideration for the option consists of cash, a promissory note, shares of common stock, and warrants, all convertible or exercisable at $12 per share, and the estimated transaction value is approximately $45 million.
BiomX’s CEO, Michael Oster, said the transaction marks the company’s entry into the defense and security sector, positioning it to capture demand in counter‑UAS, perimeter security, and critical infrastructure markets that are projected to reach more than $14 billion by 2030. The deal represents a strategic pivot from BiomX’s former phage‑therapy focus toward a high‑growth defense technology business.
DFSL’s platform combines laser‑based sensing with AI algorithms to detect unmanned aerial vehicles and ground‑based intruders, achieving approximately 99 % detection accuracy in real‑world deployments. The company’s technology is already deployed in military operations and transportation infrastructure, giving it a proven track record in the defense market.
BiomX’s financial position underscores the risk of the pivot. The company reported an EBITDA loss of $28 million over the last twelve months and a current ratio of 0.87, indicating liquidity pressures. Its market capitalization is $8.6 million, and it has received a non‑compliance notice from NYSE American regarding stockholders’ equity requirements, with an auditor’s going‑concern qualification. These factors highlight the financial challenges that accompany the strategic shift.
Investors reacted positively to the announcement, reflecting confidence in the large counter‑drone and perimeter security markets, which are projected to reach $14 billion and $130 billion respectively by 2030, with some estimates suggesting the counter‑UAS market could reach $20.31 billion. The acquisition is expected to accelerate BiomX’s entry into these high‑growth segments, but the company’s current financial pressures and regulatory compliance issues remain significant headwinds.
The option agreement’s terms, including the $12 conversion price and the mix of cash, debt, equity, and warrants, provide BiomX with flexibility to structure the transaction in a way that balances immediate capital needs with long‑term growth potential. The transaction also aligns with BiomX’s broader strategy of moving into advanced technology sectors, as evidenced by recent leadership changes and the addition of a former Mossad deputy to its advisory board.
Overall, the option agreement represents a material event that could reshape BiomX’s business model, expand its product portfolio into a rapidly growing defense market, and potentially improve its financial outlook if the acquisition is successfully integrated. However, the company’s liquidity constraints and regulatory compliance risks underscore the importance of monitoring its execution and financial performance in the coming quarters.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.